EDGE
21.2.2021 17:53:06 CET | Business Wire | Press release
SIGN4L, a dynamic provider of agile and adaptive electronic warfare and intelligence (EW&I) solutions, today launched two state-of-the-art solutions that are set to offer a tactical advantage in the missions of tomorrow. V-Protect, a radio frequency (RF) communication jamming system, and NavControl-G, a specialised counter-drone capability, are well positioned to become game-changers in shaping favourable outcomes in an increasingly digitalised defence landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210221005031/en/
The solutions were unveiled at the EDGE pavilion at the ongoing International Defence Exhibition and Conference (IDEX 2021) that runs until 25 February at the Abu Dhabi National Exhibition Centre (ADNEC).
V-Protect is an advanced mobile active and reactive high-power jammer system aimed at helping block common terrestrial RF signal technologies as well as portable satcom equipment, spanning radio, walkie-talkie, mobile and Wi-Fi frequencies. Boasting a counter-improvised explosive device (C-IED) and counter-drone measures, the user-friendly model is to be installed in a standard SUV and offers automatic operability by utilizing 16 channels and high emitting power amplifiers to provide support in enhancing protection range and combatting various threats across the frequency domain.
NavControl-G is a sophisticated transmitter unit designed to help prevent unmanned aerial vehicles (UAVs) from trespassing into specific locations. To help safeguard a sensitive area, the system can emulate GPS signals to generate position and timing inaccuracies, thereby taking control of non-cooperating unmanned vehicles. Encased in a shock-proof container, the system can be seamlessly integrated across multiple configurations - either in fixed locations or deployed on the field when required.
Waleid Al Mesmari, Vice President of Program Management for the Electronic Warfare & Intelligence cluster at EDGE, said: “Electronic warfare and intelligence make up the backbone of modern defence and security systems. SIGN4L is at the frontlines in pioneering breakthrough technologies that help our clients expand their options in a rapidly changing world. By assisting our clients with the management of their complex security and performance requirements, our latest solutions are prime examples of our agile offerings at work that focus energy to obscure, neutralise and attack adversaries.”
SIGN4L brings a startup ethos to designing and producing state-of-art open-architecture digital and RF-based security products and services for governments and businesses in the region. The company has implemented a rigorous cycle of threat analysis, research, and development to monitor, analyse and counter emerging risks. SIGN4L is part of the Electronic Warfare & Intelligence cluster at EDGE, an advanced technology group that ranks among the top 25 military suppliers in the world.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210221005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom